### **NHS** Blood and Transplant

# HLA Matched Red Cells for Renal Transplant Patients

**Dr Fiona Regan** 

NHS Blood and Transplant & Imperial College Healthcare NHS Trust

# Background:



- Average kidney transplant lasts 10-15 yrs;
  - rejection is commonest cause of its failure
- "treatment" of DSA graft rejection is poor, so mechanisms to prevent DSA are focus
- - Only transfusion is modifiable (review factors Scarnick. Am J Transpl 2011)



# Background: ctd

- Association of Tx with ↑DSA
  - Willicombe, abstract Renal Ass'n/BRS, Glasgow 2014;
  - Redfield, Nephrol Dial Transpl 2016.
- Even LD blood still a problem as:
  - Lymphocytes 2x10^5 class I HLA per cell
  - Rbc 2x10^3 class I HLA per cell but 1000x rbc:wbc in unit of red cells (LD);
- (kidney donor transfusion in 1970-80s improved transplant outcome, as 1yr graft survival 60-70%; but now 90% & better IS, so effect not evident)

### Factors in HLA Sensitisation

- Effect of Tx: down-regulatory in naïve patients but stimulatory in previously exposed patients, so HLA Ab's in transplant candidates is:
- 10-12% if Tx up to 20 units, if no previous pregnancy/transplant.
  When produced, were low level & disappeared in months, even if further Tx
- 2. Age: 35% HLA sensitisation in age 5-20 versus 7.5% in age >20
- 3. Pregnancy alone: 5-33% HLA sensitisation (∞ technique)
- Tx & pregnancy: 40% vs 5% with no Tx; & higher titre & broad sensitisation



- A) Does Tx cause HLA Ab's to ag's from the Tx, which are also on kidney (DSA), so that HLA matched blood would prevent this, OR
- B) Does Tx cause general "immune stimulation" so that HLA Ab's formed (resurged from previous cause) even though Tx did not contain corresponding HLA ag's – therefore HLA matching of blood, would NOT prevent this
- Need to determine if patients who form HLA Ab's after Tx, received Tx with the corresponding ag on

Study:



### Renal Transplant Team, IC and NHSBT collaboration

- All renal transplant patients who were transfused: selected
  - 164 who developed kidney donor-specific antibodies (DSA) posttransplant
  - 164 controls, who didn't develop DSA
- To identify if donors of components had corresponding ag to HLA (DSA) Ab developed, needed to HLA type all donors
- IC: list of unit nos: of all components transfused Maggie Przybysiak: looked up identity of all donors on PULSE
  - list of donors to Colin Brown, H&I previously HLA typed?
  - rest to contact for HLA typing need consent therefore for extra samples
  - needed ethics, R&D and BSCARE approvals

### **Flow Diagram for HLA Ab Study**







 Designed with H&I (Andrea Harmer, Colin Brown), Donor Services (Nicky Anderson, Jane Griffith – Area Nurse Manager, Eileen Bailey – NCC)

- Estimated up to 10% might fail saliva kit test - so need blood sample

- Before contacting donors checked all alive (on NHS Spine)
  - If donors suspended/withdrawn F. Regan & in some cases, CST Drs Colindale – judged on PULSE reasons, if ok to contact
- Letters to donors (batches per week)
  - Info leaflet with consent form and SAE
  - Offer to answer queries
  - Send saliva kit once consent received: prepaid box to post back to
    F. Regan & PA
  - Chase up letter 1 month, if no reply

# Testing

- H&I test in batches of 90
  - Paid for on basis would get lot of HLA typed red cell donors out of it, in case need to HLA Match in future!
- Donors warned testing up to 6 weeks later, so may get letter to say "need blood sample" after that
  - Very few needed blood sample: 6 of 150 tested (4%)
- Agreed with Donor Teams nationally that if donor wanted sample taken at session, check with Area Manager first (to avoid overload); fully supportive of Study
  - Had letters with instructions and donors post sample
- Comms: Article in Connect and Donor Magazine for staff and donor awareness



• 12 • B I U 圖書書圖篇集• 語言律律 🗄 • 🎶 • 🗛 • 💂



#### HLA TYPING RENAL STUDY 2015-2017 (RESPONSE RATE = 394/625 = 63%)

Completed 6 needed BLOOD SAMPLE	394	
incl. 27 with 'Medical Condition', 16 Suspended/Active (incl. 1 Opt Out of Comms), 12 'Opt Out of Comms', 2 Withdrawn (CLI/ Veins), 1 Withdrawn-Xfer to Wales, 8 Withdrawn for own request (incl. 1 Retired from donating), 32 DNA (incl.1 Opt Out of Comms), 8 DNA/Archived, 4 Moved.		
Chasing sample boxes (ie: signed Consent Forms)	19	
incl. 1 with 'Medical Condition' (16 chasing since 2016, 3 sent boxes recently), 1 Withdrawn (CLI/Underweight), 1 Opt Out of Comms, 1 Archived.		
Chasing Consent Foms	150	
incl. 6 with 'Medical Condition', 2 Suspended, 60 Withdrawn (38 DNA-incl.1 Opt Out of Comms, 9 DNA/Archived, 3 Moved, 6 Moved/Archived, 4 Withdrawn for own request).		
Did not want to take part	41	
incl. 5 with 'Medical Condition', 1 Withdrawn (CLI/VV3), 4 Non UK address (incl. 1 Retired, 1 DNA, 1 Withdrawn for own request, 1 Moved/Archived), 2 DNA, 1 DNA/Archived, 2 Withdrawn for own request, 1 Retired due to age, 2 Moved, *2 agreed (sample box sent)/Disagreed*.		
Wrong address/No e-mail address	17	
(incl. 4 that unable to find in NHS Spine)		
Deceased (identified in NHS Spine: not contacted)	4	
Total	625	

#### BREAKDOWN of donors contacted with Medical Condition (n= 39)

• Completed: 27

- Awaiting sample box: 1
- Declined: 5
- No response: 6 (Chasing Consent Forms)

#### **LIST OF DONORS WITH MEDICAL CONDITIONS – Total 39**

COMPLETED:
Pernicious anaemia (gastro)
Celiac Disease
Splenomegaly
Malignancy x3
Cardiovascular x4
Vasovagal
Anaemia x2
3 <sup>rd</sup> Consecutive Low Hb
Investigations
Renal condition
Drug Induced Hepatitis
High BP
TDW Post 1980
Lymphedema (leg cellulitis)
Dizzy episode
Low grade ductal carcinoma in situ
Colon Polyp – recovered
Stent fitted – narrow artery
Lump
Fractured Finger
Shoulder Injury



# Non-"active" donors on PULSE, who completed study (n=68):

# Suspended/returning to Active – 16 (4% of all who completed)

(incl. 1 'opt out comms') due to malaria, endoscopy, pregnancy, Low Hb, investigations, own request

### Didn't attend blood session/Moved/Archived - 42 (10.6%)

(incl. 3 'opt out comms')

### Withdrawn – 2 (0.5%)

Clinical conditions (2 no suitable veins)

### Withdrawn for own request -8 (2.3%)

(incl. 1 retired from blood donation)



### **Results** (So far 108 donors tested)

- HLA typed 108 blood donors of 36 patients
  All 36 patients developed de novo DSA post-transfusion
- 54/108 transfusions resulted in a Transfusion Specific Antibody (TSA): this was in 29 patients
- 33/108 transfusions resulted in a TSA which was the same specificity as the DSA: this was in 17 patients
- (completing further HLA typing by end of May: total 394 donors), plus 43 already HLA typed

# Censored allograft survival (in TSA+=DSA+ patients v TSA-DSA+ and TSA+ $\neq$ DSA+ patients)



### AMR free survival (in TSA+=DSA+ patients v TSA-DSA+ and TSA+ ≠ DSA+ patients)





### Where next?

- Early results: need further numbers to analyse
  - 316 HLA typed now;
  - total samples received = 394;
- Funding application to extend to larger study, to ascertain whether this is true finding.
- Abstract to BRS Meeting in March 2017

